NCT02843230 is a clinical trial of Avastin in Glioblastoma, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT02843230?

NCT02843230 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT02843230?

Interventions in NCT02843230: Avastin, Lomustine, Temozolomide, MRI, MRS, DSC.

What condition does NCT02843230 study?

NCT02843230 studies Glioblastoma.

Is NCT02843230 still recruiting?

NCT02843230 is currently completed. Last updated 8 April 2022.

Last reviewed 2022-04-08 · How we verify

NCT02843230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI

Completed Last updated 8 April 2022

What this trial tests

trial testing Avastin in Glioblastoma in 30 participants. Completed in 31 January 2022.

Timeline

1 August 2016

Primary endpoint
31 January 2022

31 January 2022

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 August 2016
Primary completion	31 January 2022
Estimated completion	31 January 2022
Sites	1 location across United States

Drugs / interventions tested

Avastin — full drug profile →
Lomustine (LOMUSTINE) — full drug profile →
Temozolomide (temozolomide) — full drug profile →
MRI — full drug profile →
MRS
DSC

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study aims to predict treatment response to anti-angiogenic therapy (Avastin) using advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) for Glioblastoma patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma.
Talati P, El-Abtah M, Kim D, Dietrich J, et al · · 2021 · cited 11× · PMID 34131648 · DOI 10.1093/noajnl/vdab060
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.
El-Abtah ME, Wenke MR, Talati P, Fu M, et al · · 2022 · cited 10× · PMID 34751617 · DOI 10.1148/radiol.2021210826
Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).
Sharma B, Agriantonis G, Shafaee Z, Twelker K, et al · · 2024 · cited 4× · PMID 39682237 · DOI 10.3390/cancers16234051

Verify or expand the search:

Other trials of Avastin

Trials testing the same drug.

NCT07527832 — An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan. · not yet recruiting
NCT05446870 — Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) · Phase 2 · completed
NCT05110118 — Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male · Phase 1 · completed
NCT05318443 — A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer · Phase 3 · completed
NCT03676192 — To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or R · Phase 3 · completed

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02843230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 8 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing